This therapeutic concept uses PROteolysis TArgeting Chimeras (PROTACs) — heterobifunctional small molecules that recruit endogenous E3 ubiquitin ligases to selectively ubiquitinate and degrade pathological tau protein via the ubiquitin-proteasome system. Unlike stoichiometric tau inhibitors or immunotherapy, PROTACs operate catalytically: a single molecule can destroy multiple tau copies before being recycled. By engineering selectivity for hyperphosphorylated or aggregation-prone tau conformers — while sparing physiological tau needed for axonal microtubule stability — this approach could achieve disease-modifying clearance of the toxic species driving Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and other tauopathies.[1][2]
Tau pathology is the strongest correlate of cognitive decline in AD and the primary driver of 4R-tauopathies like PSP and CBD. Current anti-tau antibodies (semorinemab, zagotenemab, bepranemab) have shown disappointing clinical results, likely because they cannot access intracellular tau — where the majority of pathological species reside.[4] PROTACs solve this: as cell-permeable small molecules, they degrade tau inside neurons at the site of toxicity.
Key mechanistic advantages:
Tau NFT burden correlates with Braak staging and cognitive decline more tightly than amyloid-beta plaque load.[6] Degrading intracellular pTau could arrest the tau seeding and propagation cascade that drives disease progression from entorhinal cortex to neocortex.
4R-tau isoforms form distinct fibrillar conformers in PSP (straight filaments) and CBD (wide filaments). PROTAC warheads derived from 4R-selective PET tracers could specifically target these disease-causing conformers while leaving 3R-tau unaffected.[7]
MAPT mutations causing FTD-tau produce gain-of-function aggregation-prone tau. Targeted degradation eliminates the toxic gain-of-function without requiring gene silencing.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | No tau-PROTACs in clinical development; first-in-class for intracellular tau degradation |
| Mechanistic Rationale | 9 | Tau degradation validated genetically; PROTAC modality proven for other CNS targets |
| Addresses Root Cause | 8 | Directly eliminates the pathological species most correlated with neuronal death |
| Delivery Feasibility | 5 | CNS PROTAC delivery remains challenging (MW, efflux); requires significant medicinal chemistry optimization |
| Safety Plausibility | 6 | Risk of degrading physiological tau; must validate conformer selectivity rigorously |
| Combinability | 8 | Orthogonal to amyloid-targeting therapies, anti-inflammatory approaches, and tau immunotherapy |
| Biomarker Availability | 9 | CSF pTau 181/217/231, tau PET (flortaucipir, MK-6240), plasma pTau all validated[8] |
| De-risking Path | 7 | iPSC neurons, tau transgenic mice, and established PET/CSF endpoints available |
| Multi-disease Potential | 9 | AD, PSP, CBD, FTD-tau, CTE, PART — any tauopathy with accessible pathological conformer |
| Patient Impact | 9 | Could halt or reverse the dominant pathological driver of cognitive decline in tauopathies |
| Total | 79 |
| Milestone | Activities | Duration | Estimated Cost |
|---|---|---|---|
| M1.1 Target validation | Cereblon/VHL engagement assays, tau binding selectivity for 4R vs 3R | 3 months | $200,000 |
| M1.2 PROTAC library | Screen 500+ PROTAC conjugates; focus on BBB-penetrant linkers | 6 months | $350,000 |
| M1.3 Lead optimization | 20-30 analogs with varying linker chemistry, E3 ligase recruiters | 6 months | $400,000 |
| M1.4 In vitro PK/ADME | Plasma protein binding, BBB permeability (PAMPA), microsomal stability | 3 months | $80,000 |
| M1.5 In vivo PK | Rodent PK, brain exposure studies | 4 months | $120,000 |
Phase 1 Total: ~$1,150,000
| Milestone | Activities | Duration | Estimated Cost |
|---|---|---|---|
| M2.1 Efficacy models | PS19 tauopathy mice, 3xTg-AD; tau PET, behavioral testing | 6 months | $280,000 |
| M2.2 GLP toxicology | 28-day rat, 14-day dog; PK/toxicokinetics | 6 months | $450,000 |
| M2.3 IND-enabling CMC | Scale-up, formulation, stability | 4 months | $200,000 |
Phase 2 Total: ~$930,000
| Milestone | Activities | Duration | Estimated Cost |
|---|---|---|---|
| M3.1 Phase 1a SAD/MAD | Healthy volunteers, safety/PK | 8 months | $1,800,000 |
| M3.2 Phase 1b | PSP/CBS patients, biomarker (tau PET) | 6 months | $2,200,000 |
| M3.3 Phase 2 | Randomized in 80 PSP patients | 12 months | $4,000,000 |
Phase 3 Total: ~$8,000,000
| Institution | Investigator | Relevance | Contact Status |
|---|---|---|---|
| UCSF | Dr. Gil Rabinovici | Tau PET imaging, clinical trials | Imaging partner |
| Mayo Clinic Rochester | Dr. Keith Josephs | PSP neuropathology, clinical expertise | Trial site |
| University College London | Dr. Rohan de Silva | Tau biology, 4R-tau expertise | Scientific advisor |
| Banner Sun Health | Dr. Thomas Beach | Brain bank, neuropathology | Tissue access |
| Washington University | Dr. Randall Bateman | Tau kinetics, CSF biomarkers | Biomarker partner |
| Company | Program | Stage | Partnership Potential |
|---|---|---|---|
| TauRx | LMTX (methylene blue) | Phase 3 | Data sharing, competitive analysis |
| Biogen | Anti-tau antibodies (gosuranemab) | Phase 2 | Combination therapy |
| Eli Lilly | Tau PET tracer, antibodies | Various | Imaging partnership |
| C4 Therapeutics | Cereblon PROTAC platform | Discovery | Technology licensing |
| Arvinas | PROTAC platform, VHL-based | Preclinical | Co-development |
| Risk | Likelihood | Impact | Mitigation Strategy |
|---|---|---|---|
| 4R-tau selectivity | High | High | Screen against 3R-tau; structural optimization for 4R binding pocket; backup to pan-tau degrader |
| BBB penetration | Medium | High | Use frontier analysis; test multiple linker types; intrathecal backup |
| E3 ligase toxicity | Medium | Medium | Use cereblon (well-characterized); include cereblon levels in patient stratification |
| Zombie effect | Low | Medium | Monitor for accumulation; PK/PD modeling; intermittent dosing |
| Tau isoform expression | Medium | Medium | Patient selection based on tau isoform (4R for PSP); biomarker stratification |
Sakamoto KM, Kim KB, Kumagai A, et al. "Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation". Proceedings of the National Academy of Sciences. 2001. ↩︎ ↩︎
Crews CM. "Targeting the undruggable proteome: the small molecules of my dreams". Chemistry & Biology. 2010. ↩︎
von Bergen M, Friedhoff P, Biernat J, et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming beta structure. Proceedings of the National Academy of Sciences. 2000. ↩︎
Teng E, Manser PT, Pickthorn K, et al. "Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial". JAMA Neurology. 2022. ↩︎
Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies — still a challenge. Molecular Psychiatry. 2019. ↩︎
Nelson PT, Alafuzoff I, Bigio EH, et al. "Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature". Journal of Neuropathology & Experimental Neurology. 2012. ↩︎
Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature. 2021. ↩︎
Barthélemy NR, Horie K, Sato C, Bhatt DK. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. Journal of Experimental Medicine. 2020. ↩︎